Literature DB >> 7248786

Postmortem stability of alpha-bungarotoxin binding sites in mouse and human brain.

P Davies, S Feisullin.   

Abstract

The postmortem stability of alpha-bungarotoxin binding sites was examined in the brains of mice handled under conditions designed to simulate the handling of human autopsy material. No significant changes in the concentration of binding sites were evident up to 24 h after death. No correlation between the number of binding sites and the delay period between death and autopsy was found in studies of frontal cortex or mid-temporal gyrus from normal humans or cases of dementia of the Alzheimer type. Samples of mid-temporal gyrus from demented patients show a significant reduction in the number of binding sites.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248786     DOI: 10.1016/0006-8993(81)90148-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

1.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia.

Authors:  E D London; M J Ball; S B Waller
Journal:  Neurochem Res       Date:  1989-08       Impact factor: 3.996

Review 3.  Nicotinic ACh receptors as therapeutic targets in CNS disorders.

Authors:  Kelly T Dineley; Anshul A Pandya; Jerrel L Yakel
Journal:  Trends Pharmacol Sci       Date:  2015-01-29       Impact factor: 14.819

Review 4.  Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer's Dementia: An Update.

Authors:  Justin L Hoskin; Yazan Al-Hasan; Marwan Noel Sabbagh
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

5.  [(125)I]Iodo-ASEM, a specific in vivo radioligand for α7-nAChR.

Authors:  Yongjun Gao; Ronnie C Mease; Thao T Olson; Kenneth J Kellar; Robert F Dannals; Martin G Pomper; Andrew G Horti
Journal:  Nucl Med Biol       Date:  2014-12-20       Impact factor: 2.408

6.  Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases.

Authors:  E K Perry; R H Perry; C J Smith; D J Dick; J M Candy; J A Edwardson; A Fairbairn; G Blessed
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

7.  Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro.

Authors:  Richard T Reid; Marwan N Sabbagh
Journal:  J Neural Transm (Vienna)       Date:  2008-08-26       Impact factor: 3.575

Review 8.  Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration.

Authors:  Concepcion Conejero-Goldberg; Peter Davies; Luis Ulloa
Journal:  Neurosci Biobehav Rev       Date:  2007-11-28       Impact factor: 8.989

Review 9.  The nicotinic acetylcholine receptor: smoking and Alzheimer's disease revisited.

Authors:  Mona Mehta; Abdu Adem; Maninder S Kahlon; Marwan N Sabbagh
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

10.  Brain imaging of nicotinic receptors in Alzheimer's disease.

Authors:  Jin Wu; Masatomo Ishikawa; Jichun Zhang; Kenji Hashimoto
Journal:  Int J Alzheimers Dis       Date:  2010-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.